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Abstract 
Background: Smoking in one of the most serious public health problems. It is well known that it constitutes a major 
risk factor for chronic diseases and the leading cause of preventable death worldwide. Due to high prevalence of 
smokers, new cost‑effective strategies seeking to increase smoking cessation rates are needed.
Methods: We performed a Markov model‑based cost‑effectiveness analysis comparing two treatments: health 
advice provided by general practitioners and nurses in primary care, and health advice reinforced by sending motiva‑
tional text messages to smokers’ mobile phones. A Markov model was used in which smokers transitioned between 
three mutually exclusive health states (smoker, former smoker and dead) after 6‑month cycles. We calculated the 
cost‑effectiveness ratio associated with the sending of motivational messages. Health care and society perspectives 
(separately) was adopted. Costs taken into account were direct health care costs and direct health care cost and costs 
for lost productivity, respectively. Additionally, deterministic sensitivity analysis was performed modifying the prob‑
ability of smoking cessation with each option.
Results: Sending of text messages as a tool to support health advice was found to be cost‑effective as it was associ‑
ated with increases in costs of €7.4 and €1,327 per QALY gained (ICUR) for men and women respectively from a 
healthcare perspective, significantly far from the published cost‑effectiveness threshold. From a societal perspective, 
the combined programmed was dominant.
Conclusions: Sending text messages is a cost‑effective approach. These findings support the implantation of the 
combined program across primary care health centres.
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Background
Smoking in one of the most serious public health prob-
lems [1]. It is well known that it constitutes a major risk 
factor for chronic diseases and the leading cause of pre-
ventable death worldwide [2]. In Spain, according to the 
12th Survey on Alcohol and other Drugs (EDADES), 34% 
of people between 15 and 64  years old admit to smok-
ing on a daily basis in the past month, which represents 
an increased rate compared with rates (30 and 31%) 
from previous surveys (2011, 2013 and 2015) [3]. Smok-
ing is associated with higher healthcare costs, with an 
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estimation of €864.64/year in smokers versus €474.71/
year in non-smokers according to a study by the Spanish 
Society of Pulmonology and Thoracic Surgery [4].
Currently, there are various different treatments for 
smoking cessation, including more or less intensive inter-
ventions based on motivational advice, pharmacological 
therapy and group-based programs, with variable suc-
cess rates depending on the therapy used [5]. On the 
other hand, since every year more than 70% of the popu-
lation goes to primary care room, and they are attended 
an average of 6–7 times, this privileged situation allows 
for repeated interventions in which the smoker is more 
receptive to motivational advice because of the trust they 
have with their doctor and/or nurse [6]. For this reason 
we must take advantage of the opportunity provided by 
primary care to provide this type of intervention from 
there. In Spain, several studies have been conducted to 
evaluate tobacco cessation interventions at this level with 
satisfactory results [7, 8]. Interestingly, some smokers 
decide to quit smoking without any support, with success 
rates varying from 3 to 8% after 6 months [9, 10].
The provision of health advice is considered one of the 
most cost-effective interventions for smoking cessation 
[11]. However, changes stimulated by such advice do not 
last over time [12] and hence, there is a need to establish 
approaches for reinforcement, including the use of infor-
mation and communication technologies, and specifically 
m-health (health through mobile technologies) for which 
there is evidence in smoking cessation [13–16]. Mobile 
phone based interventions are more effective that routine 
clinical practice, according a meta-analysis of six clini-
cal trials carried out by Whittaker et  al. [13] 1.83 (95% 
CI 1.54–2.19), being results similar to those reported by 
other research groups [14–16].
We carried out a randomized clinical trial to assess 
the effectiveness of a combined program SMSalud® 
that included sending motivational messages by mobile 
phone to smoker people who sought help from primary 
health professionals, finding 16.25% of abstinences rates 
at 12  months versus 5.6% of standard care group) [16]. 
Further, with the deployment of mobile networks in the 
nineteen-eighties, the use of mobile phones has grown 
exponentially. The International Telecommunications 
Union estimated that by the end of 2015 there would be 
7 billion mobile phones across the world, corresponding 
to a penetrance of 97% [17], and their increasingly wide-
spread use makes these devices ever more useful tools in 
healthcare.
Assuming that mobile phones are useful tools in health-
care, it seems reasonable to explore strategies focused on 
using mobile technology to improve smoking cessation. 
Although the combined program SMSalud® has shown 
to be effective as a tool to reinforce health advice provide 
in primary care health professionals, and the results of 
Guerriero et al. [18] suggest that it would be a cost-effec-
tive tool, there is a need for long-term specific economic 
assessment prior its implementation in the primary care 
setting. Taking all this into consideration, the main objec-
tive of the present article was to assess whether the use 
of text messages as a support tool for health advice is a 




We performed a Markov model based cost-effectiveness 
analysis to calculate the incremental cost-effectiveness 
ratio (ICUR), which is a measure that compares differ-
ences in costs and differences in effectiveness between 
the options considered.
To estimate the costs and clinical outcomes from the 
start of the intervention until patient death, we used a 
Markov model that has been used previously in eco-
nomic assessments [18–20]. This Markov model consists 
of three mutually exclusive health states (smoker, former 
smoker and dead), to simulate the process of smoking 
cessation in a hypothetical cohort of 1000 smokers aged 
16 years old or above. Specifically, we opted for a model 
with cycles of 6  months, in which people transitioned 
between the three health states, with transition probabili-
ties differing as a function of time, age and sex (Fig.  1). 
All people started the model in the smoker state, and in 
the first cycle, could then stop smoking, continue smok-
ing or die. From the second cycle onwards, participants 
could continue to not smoke, continue to smoke, start 
smoking again or die. Additionally, both smokers and 
former smokers could develop smoking-related diseases 
(myocardial infarction, stroke, heart disease, chronic 
obstructive pulmonary disease or lung cancer), with dif-
ferent probabilities as a function of age and gender. For 
calculating the incremental cost associated with the rein-
forcement provided through mobile text messaging, the 
time horizon was set to be the patient´s entire life. This 
time frame allowed us to include both the health impact 
and all the costs associated with smoking over a patient´s 
life and thus explore the reduction in costs and improve-
ment of quality of life due to the use of reinforcing text 
messaging.
As well as having implications for the health of smok-
ers, it also has a major impact on public finances in both 
the short and long term, since tobacco-related diseases 
are chronic diseases that cause high health expenditure. 
The probability of suffering from these diseases increases 
with the age of the patient, so it is necessary to include 
the time horizon of the patient’s entire life.
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A discount rate of 3% was used for updating future 
costs and health benefits. This discount rate is widely 
used in long-term cost-effectiveness studies [21–23]. The 
analysis was conducted from a health system perspective 
including all the costs related to the intervention pro-
vided and costs related to the five SRD and from a soci-
etal perspective including in addition to all the above, 
the costs due to loss of productivity caused by sick leave 
associated with the five diseases most strongly associated 
with smoking.
Alternatives
The study was based on the aforementioned clinical trial 
in which we assessed the effectiveness of the combined 
program, SMSalud®, comparing it with health advice 
alone [16].
We compared the following two treatment options: (a) 
Usual clinical practice carried out in primary care health 
centers- health advice provided by general practitioners 
and nurses responsible for smoking cessation manage-
ment (verbal and written information on the benefits of 
not smoking and recommended changes in eating habits) 
[16], and (b) the same health advice complemented by the 
sending of motivational and supportive messages to the 
patient´s mobile phone during the 6 months the program 
lasted (combined program). Health advice was provided 
repeatedly (at 7 days, 4, 12 weeks and at 6 months since 
the quitting day). In both cases, the treatment lasted 
6  months. Smokers who participated in the previous 
clinical trial had a mean age of 45 years old (SD 9.1). The 
55.94% of participants were men and they were included 
in the study if they obtained a score of > 4 on the Rich-
mond test and if they didn’t have depression. The per-
centage of patients who quitted smoke at 6 months was 
24% (95% CI 31–17.72%) and 12% (CI 95% 6.686–16.88%) 
in the intervention and control group respectively. At 
12 months smoking cessation rates were 16.25% (95% CI 
10.53–21.97) and 5.6% (95% CI 2.04–9.16) [16].
Participants on the combined program received two 
automatically-generated text messages a day (one in the 
morning and one in the evening) for the first 5 weeks and 
three messages a week from weeks 6 to 26. At 26 week, 
the program finished. The messages were motivational in 
intent, to encourage people in their efforts to stop smok-
ing, and also provided information about the health-
related risks of smoking. Participants could also request 
supportive messages from the system in moments of cri-
sis or anxiety. For this, they had to send a message free 
of charge with the word “anxiety” or “relapse” to a given 
phone number [16].
Probabilities
The probabilities of smoking cessation and relapse used 
in this cost-effectiveness study are taken from our previ-
ous clinical trial [16] in 320 smokers. In this clinical trial, 
24% (95% CI 17.72–31%) of people who received rein-
forcement messages stopped smoking after 6  months, 
compared to 12% (95% CI 6.86–16.88%) of people 
assigned to health advice alone, not founding statistically 
significant differences in success rates between men and 
women. The rates of relapse were 33% and 53% in the 
Fig. 1 .
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groups receiving health advice plus reinforcement mes-
sages and health advice alone respectively (Table 1).
We assumed an annual rate of relapse of 10% from the 
first year [24], based on a meta-analysis of clinical trials 
and prospective studies, and an annual rate of smoking 
cessation of 2% [25], regardless of the therapy used, age 
and gender, from the second cessation attempt onwards, 
this figure also having been used in previous studies 
[18]. We also assumed that each patient could make two 
attempts at quitting smoking each year, in line with data 
from the Spanish National Health Survey [26] (Table 1).
In the absence of valid data from the Spanish popula-
tion on mortality rates by age and smoking habits, we 
used figures for the British population by age and smok-
ing habits (smoker, former smoker), calculated in 1994 
by Doll et  al. [27]. However, before their inclusion in 
the model, we calibrated these rates seeking to repro-
duce mortality rates in men and women in the Spanish 
population in 2018, by applying a corrective factor; the 
same to smokers and former smoker, which have been 
subsequently corroborated with the mortality rates pro-
vided by the National Institute of Statistics for the year 
2018. This procedure has been used by other groups of 
researchers in cost-effectiveness studies published in 
recent years [18, 28].
To calculate the number of smokers and former smok-
ers who might develop a smoking-related disease in each 
cycle, we multiplied the number of smokers/former 
smokers in each cycle by the incidence of each disease by 
age and gender (when such disaggregated data were avail-
able) (Table 1) [29–32] and the excess risk of developing 
each disease in the case of smokers and former smokers 
(Table 1) [33–35].
Similarly, we calculated the prevalence of each disease 
as a function of smoking status:
The data on prevalence (Table  1) of the different dis-
eases considered were taken from the study by Flack et al. 
on interventions for smoking cessation [19]. According 
to this study, the prevalence rates increased with age and 
differed as a function of gender.
Health benefits
The values for health-related quality of life (Table 1) of the 
five smoking-related diseases [36] in healthy population 
Disease incidence = (Disease incidence in former smokers ∗Number of former smokers)
+ (Disease incidence in smokers ∗Number of smokers)
Disease prevalence = (Disease prevalence in smokers ∗ Prevalence of smokers)
+ (Disease prevalence in former smokers ∗ Prevalence of former smokers)
and the corresponding decrease associated with myo-
cardial infarction, stroke, chronic obstructive pulmonary 
disease, and heart disease were taken from the 2011–
2012 Spanish National Health Survey, disaggregated 
by age and sex, and assessed using the EuroQol 5D-5L 
[37]. In the case of lung cancer, the decrease of health-
related quality of life was assessed using the results of 
Trippoli et al. [38]. Further, the data on the quality of life 
of smokers and former smokers with no comorbidities 
were obtained from a study by Tillmann et al. conducted 
in 1997 [39]. As in previous studies, when patients had 
more than one comorbidity, we applied the lowest utility 
value [18].
Costs
In the cost analysis from a healthcare perspective, we 
only include direct healthcare costs related to the inter-
vention administered (cost of the text messaging, cost of 
the messages sent, and costs associated with the visits to 
health professionals) and related to the smoking related 
diseases-SRD) [40]. All the costs (Table 2) are expressed 
in euro for 2018, corresponding inflation rates being 
applied for each year.
Regarding the analysis from the social perspective, we 
assumed the direct healthcare costs specified in the previ-
ous paragraph and also losses of productivity due to SRD 
(Table 2) [41–46]. We estimated the disease-related loss of 
productivity as the reduction in productivity of a worker 
who is ill or unable to work. Further, for calculating the 
loss of productivity due to sick leave, we considered the 
percentage of male and female smokers and former smok-
ers in work, the hourly earnings for men and women, and 
the mean number of monthly agreed working hours for 
men and women, all these data being obtained from the 
Spanish National Statistics Institute [47].
In order to estimate indirect costs and transform them 
into monetary units, we used the human capital approach 
[48–50]. This approach converts life years into monetary 
equivalents considering the mean gross income of each 
worker. The method is based on the hypothesis that the 
value of the lost production is equivalent to the wage 
associated with obtaining the aforementioned produc-
tion. That is, a day off work represents a loss of produc-
tion equal to the wage for that same day worked [51]. 
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Table 1 Data entered into the model
Inputs Source
Mortality By smoking status (smoker, former smoker) 27
Prevalence of smoking‑related diseases Myocardial infarction 19
Heart disease
Chronic obstructive pulmonary disease
Lung cancer
Stroke






Chronic obstructive pulmonary disease
Lung cancer
Stroke















Male 8.78/ Female 7.48














































Number of attempts at smoking cessation 2 26
Utilities Smoker with no comorbidities
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With this methodology, a single wage, often the mean or 
the minimum, is applied to all analyzed people. Interest-
ingly, a study published by Suarez-Bonel et al. [4], dem-
onstrated that smokers and non-smokers were on sick 
leave for an average of 11 days and 7 days a year, respec-
tively. All the parameters entered into the model are 
listed in Table 1.
Model validation
The model was validated internally and externally. For the 
former, we followed all the recommendations of Halpern 
et al. [51] and Nuijten et al. [52]. In addition, according to 
McCabe et al. [53], the results of the model can only be 
properly validated in one way, that is, by comparing the 
modelled estimates with the values obtained in real life, 
which could be called predictive validity. To address this, 
we calculated the life expectancy of men and women at 
different ages based on our model and compared it with 
the figures provided by the Spanish National Statistics 
Institute (real data). For the external validation, we used 
the LYGs thanks to smoking cessation at different ages 
and the life years lost due to smoking at 40 years of age, 
comparing the results with those of Ozasa et al. [54]. In 
this particular case we considered a utility of 1 and a dis-
count of 0.
Deterministic sensitivity analysis
We performed a univariate deterministic sensitivity 
analysis to assess the change in ICUR as a function of 
the changes in the effectiveness values of the combined 
program or the motivational advice alone, and the age 
of starting program (50 years old). We have also carried 
out a multivariate sensitivity analysis modifying both 
probabilities of smoking cessation at the same time, and 
also equalizing the probability of relapse at the first cycle 
(0.5264) in the both alternatives.
The effectiveness values for the combined program 
used to perform the sensitivity analysis lie within the 95% 
confidence Interval (17.71–31%) as did the correspond-
ing values for treatment effectiveness of motivational 
advice alone (6.86–16.88%) [16].
We have also repeated the sensitivity analysis with a 6% 
discount rate.
Threshold
The reference threshold that has been employed to con-
sider or our combined program, as cost-effective is the 
Table 2 Costs included in the model
a For calculating the costs per patient, the total amount for each item was divided by the total number of patients in each group (1000)
b For calculating the costs per patient, the total amount for each item was divided by the total number of people in both groups
Combined program Health advice
Costs of each option/patient €187.90 €166.95
 Cost of general practitioner appointment (2018 portfolio of services of the Basque Health Service) €58 × 4 €58 × 4
 Cost of nurse appointment (2018 portfolio of services of the Basque Health Service) €24 × 1 €24 × 1
 Cost of nurse phone consultation (2018 portfolio of services of the Basque Health Service) €12 × 4 €12 × 4
 Cost of the text messaging program €17,385.27a
 Cost of the messages sent €3,127.85a
 Cost of two CO monitors and mouthpiece €1,891.5b
 Program logo €431.5a
Annual costs of the treatments of smoking‑related diseases
 Incidence‑related costs
  Lung cancer €13,206 44
  Stroke €5,759.50 44
  Myocardial infarction €12,987 43
  Chronic obstructive pulmonary disease €1,672 42
  Heart disease €8,578 43
 Prevalence‑related costs
  Lung cancer €13,206 44
  Stroke €3,596.60 44
  Myocardial infarction €3,046 43
  Chronic obstructive pulmonary disease €1,672 42
  Heart disease €685 43
  Training costs for the combined program €1,900
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estimated by Vallejo-Torres et  al. [55] in 2018, for the 
Spanish NHS (€22,000).
The cut-off point of smoking cessation probabilities o 
NOT cost-effectiveness identified for women when the 
probabilities of relapse are equalized are 0.177 and 0.162 
for combined program and health advice respectively.
Results
The increase in costs at short-term (at 6 months-moment 
of the end of program), associated with mobile phone 
messaging for a cohort of 1000 smoking people was 
€22,850 from a healthcare perspective. At the end of the 
program there was also a bigger percentage of people 
quitting smoking in the combined program group (244 
versus 119), which translates to an additional cost of €183 
per tobacco quitter, at this moment.
From a healthcare perspective, the increase in costs 
through the entire life of participants was €7.4 and €1,327 
per QALY gained (ICUR) for men and women, respec-
tively. From the social perspective, the alternative treat-
ment was dominant, with savings of €5,398 and €3,290 
per QALY gained (ICUR) for men and women respec-
tively (Table 3).
A deterministic sensitivity analysis was performed to 
assess whether the results were maintained when certain 
variables were modified. Table 4 shows that as the differ-
ence in the probability of quitting smoking between the 
combined program and health advice alone increases, 
both QALYs gained and ICUR increase. Table  5 shows 
that increasing the age of smoking cessation, more sav-
ing are generated for the system. Table  6 shows that 
equalizing the probability of relapse at the first cycle in 
both alternatives (0.5264) from healthcare perspective, 
the combined program is not cost effective (€ 48,998 
cost/Qaly) for the following probabilities of quitting 
tobacco (0.177 CP and 0.169 HA) in women. From soci-
ety’s perspective the model is always dominant in men. 
In women it is dominant when the probability of relapse 
is unchanged. When the probabilities of relapse are the 
same in both alternatives (0.5264) the model is cost effec-
tive for the following probabilities of quitting tobacco 
(0.177 CP and 0.119 HA) and it is not cost effective for 
the following probabilities of quitting tobacco (0.177 CP 
and 0.169 HA).  
On the other hand, when repeating the sensitivity anal-
ysis with a 6% discount rate, we have obtained very simi-
lar results.
Model validation
The life expectancy estimated from our model is very 
similar to the data provided by the Spanish National Sta-
tistics Institute for different ages (Table  7). The results 
of the external validation are shown in Tables  8 and 9. 
Smoking cessation at an age ≤ 40 or < 50 years old trans-
lates to 4.2 and 3.9 LYGs, respectively, being these results 
similar to those of Ozasa et  al. [54]. At older ages, the 
differences between Ozasa et al. and our group increase 
Table 4 Results of  the  cost-effectiveness analysis. Univariate sensitivity analysis. Changing the  probability of  smoking 
cessation
a The probability of smoking cessation with health advice alone remains constant (0.11875)
b The probability of smoking cessation with combined program remains constant (0.34275)
Assumption modified Combined programme Health advice alone
Probability of smoking cessation 0.1772a 0.24375a 0.3103a 0.0686b 0.11875b 0.1688b
 ICUR (€/QALYs)











 − 5,312 − 2,245 − 5,398 − 3,290 − 5,432 − 3,707 − 5,409 − 3,548 − 5,398 − 3,290 − 5,404 − 2,281
Table 5 Results of  the  cost-effectiveness analysis. 
Univariate sensitivity analysis. Changing the age of smoking 
cessation (50 years old)
ICUR (€/QALYs)
Healthcare perspective Societal perspective
Men  − 2,785  − 7,591.81
Women  − 796.27  − 4,351.31
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slightly. In addition, the life expectancy values calculated 
from our model and from that of Ozasa et  al. [54] as a 
function of smoking status and gender [54] at the age of 
40 years old are very similar, finding the largest difference 
in the case of smoking men (2.7 years) whereas the small-
est difference in non-smoking men (0.1 years).
Discussion
This economic assessment shows that the use of text 
messaging as a tool to support health advice is cost-effec-
tive from a health care perspective, given that it leads 
to health benefits and reduces costs. From the health-
care perspective, the ICUR is far below the threshold of 
€22,000 calculated for the Spanish health system [55]. 
The ICUR regarding the use of the combined program 
for smoking cessation compared to usual practice rep-
resents an increase in costs of €1,327 and €7.4 for each 
QALY gained for women and men, respectively.
Considering a social perspective, the combined pro-
gram is an alternative that results in savings of €5,398 
and €3,290 per QALY gained for men and women respec-
tively. These saving costs are related to the fact that for-
mer smokers have less risk of suffering from SRD. This 
entails fewer work leaves, thus generates savings costs 
from society perspective.
It is more cost-effective in men as they are at greater 
risk of developing disorders related to smoking than 
women, and proportionally, the benefits of smoking ces-
sation translate to a greater reduction in the risk of devel-
oping common smoking-related diseases in men. These 
benefits of the program are maintained when we modify 
the assumptions in the different sensitivity analyses car-
ried out.
The design selected in the present study aimed to maxi-
mize the validity of the results. In particular, a Markov 
model was chosen as the nature of the process under 
study is chronic with health states changing over time 
and associated with events due to risk exposure [23]. The 
recommendations of Halpern et al. [51] and Nuijten et al. 
[52] for selecting the data to input to the model in terms 
of costs, effectiveness and probability of smoking were 
followed. In addition, effectiveness data was selected 
from a clinical trial carried out by our research team 
[16]. Last but not least, data on costs for smoking-related 
diseases for the Spanish population, when available, and 
utility data for these diseases were obtained from the 
Spanish population.
Nonetheless, there are several limitations when inter-
preting the results of this study. First, the mortality rates 
were taken from the data of Doll et al. [27] for the Brit-
ish population corrected for smoking status, as we did 
not have access to adjusted rates for the Spanish popu-
lation. On the other hand, we calibrated these rates to 
reproduce the mortality rates for men and women in the 
Spanish population, assuming a risk that is proportional 
to the baseline risk for former smokers and smokers. 
Table 7 Internal validation of  the  model with  the  life 
expectancy for the Spanish population
Patient life expectancy for 2018




 16 years 64.77 64.77
 30 years 51.03 51.7
 50 years 31.86 31.02
Women
 16 years 70.11 69.6
 30 years 56.24 56.34
 50 years 36.76 37.4
Table 8 External validation.Years of  life gained 
after smoking cessation at different ages











Male 40 4.2 4.8
50 3.9 3.9
60 3.3 1.6
Table 9 External validation. Life expectancy as a function of smoking status at 40 years old
Smoking status Age Men Women
Our model Ozasa et al. Our model Ozasa 
et al.
Former smokers 40 years 40.03 40.8 44.2 42.4
Smokers 35.8 38.5 39.8 42.1
Non smokers 42.3 42.4 46.5 46.1
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Second, as with previous economic assessments, this 
study may potentially underestimate the benefits of rein-
forcement through text messaging as a tool to support 
health advice for smoking cessation, since it does not 
assume the effects of passive smoking reduction or other 
less common smoking-related diseases [15]. As a conse-
quence, the study may also underestimate the potential 
savings associated with the intervention, as it does not 
take into account the costs of treatment of these smok-
ing-related health problems. Third, our study was based 
on mean costs of the diseases most commonly associated 
with smoking, these figures varying with disease sever-
ity. Fourth, due to the lack of valid data on incidence of 
smoking related diseases (SRD) for Spanish smoker pop-
ulation, data on incidence of SRD come from different 
countries, but at least, all data on Incidence come from 
European Community Countries. Despite these limita-
tions, results from the present study come along with 
those reported by others: 0.5 QALYs for former smok-
ers [18], 0.069 QALYs for former smokers [56] and 0.10 
QALYs for former smokers [57]. These results are also 
consistent with previous economic assessments show-
ing that smoking cessation interventions using mobile 
phones are cost saving [18, 58] and cost effective [59].
Interestingly, the program studied herein becomes 
more cost effective as we increase the age at initiation of 
the intervention, given that it increases the probability of 
developing a smoking-related disease and the benefit of 
smoking cessation is greater, as found by Guerriero et al. 
[18] with larger savings the older the age of the study sub-
group. The numbers of YLG related to smoking cessation 
obtained in our model are very similar to those found by 
Ozasa et al. [54], at the ages of 40 and 50 years old, with 
the difference being greater above 60 years of age. A poten-
tial explanation for this difference is that the non-smokers 
from the Ozasa cohort [54] were less healthy, that is, they 
may have had health problems that made them less likely 
to smoke, and hence, the number of YLG as a result of 
smoking cessation was smaller in this older age group.
The WHO Framework Convention on Tobacco Control 
(FCTC) [60] proposed a series of measures for the pre-
vention and control of non-communicable disease. With 
the combined program our intention is to reinforce the 
measure (O) Offer-ofrecer, to help to quit tobacco use. 
The 2018 International Conference on Tobacco Control, 
held in Madrid, 14–16 June 2018, concluded that the 
measures that should be adopted by public authorities in 
Spain with regards to Article 14 of the FCTC (Demand 
reduction measures concerning tobacco dependence 
and cessation) include facilitating access by smokers to 
health professionals trained in managing smoking treat-
ments and fund clinical, behavioral and pharmacological 
interventions proven to be effective and safe in the treat-
ment of smoking.
Conclusions
The present study clearly shows that the use of moti-
vational messaging as a tool to support health advice 
provided by primary health care professionals is a 
cost-effective strategy from the healthcare perspective, 
and a dominant strategy from the societal perspec-
tive, and hence, following the recommendations of this 
aforementioned conference, such a strategy should be 
adopted. Notably, the National Institute for Health and 
Care Excellence has recently included the use of text 
messaging as an effective tool for smoking cessation in 
its recommendations [61].
The potential transfer of this program to primary 
care clinical practice is feasible given the low associated 
costs. It is estimated that at least 70% of the popula-
tion seek medical attention through their general prac-
titioner at least once a year, and smokers do so more 
often than non-smokers. Thus, primary care provides 
a great opportunity to introduce and promote our pro-
gram [62].
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